Syngene International Limited has informed the Exchange about Investor Presentation
Ref: Syn/CS/SE/IP/2023-24/Jan/09
January 25, 2024
To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268
Dear Sir/Madam,
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and nine months ended December 31, 2023. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to March 31, 2024.
The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.
This is for your information and records.
Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED
___________________ Priyadarshini Mahapatra Company Secretary and Compliance Officer
Enclosed: Investor Presentation.
Investor Presentation
January 2024
Safe harbour
Certain statements in this release concerning our future growth prospects are forward‐looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward‐looking statements.
Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.
Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Putting Science to Work
2
Contents
1
2
3
4
5
Operating Highlights
Syngene – Putting Science to Work
Syngene strengths
Financials
Shareholding and Share Information
Appendix
Putting Science to Work
3
1
Operating Highlights
Q3 and 9 Months FY24 performance
Operating Highlights
Q3 Financial Highlights
• The third quarter was underpinned by positive performance in Development and Manufacturing Services as well as in the Dedicated Centers. Performance in Discovery Services was impacted by the slowdown in biotech funding
•
In Manufacturing Services, the Company continued to make good progress on the long‐term biologics manufacturing partnership with Zoetis.
• Syngene concluded the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd. Once operational, the acquisition will add 20,000 litres of biologics drug substance manufacturing capacity to Syngene’s existing capabilities. It also includes a commercial scale, high speed, fill‐finish unit, which is an essential capability for drug product manufacturing. The facility is expected to be operational in the second half of FY25, subject to regulatory approvals.
•
In Discovery Services, the Company added an assay biology capability at the Hyderabad campus the existing Drug Metabolism and to complement Pharmacokinetics (DMPK) and Compound Management facilities
Revenue from Operations: 9% YoY
Total Revenue: Rs 8,828 Mn Reported EBITDA: Rs 2,608 Mn Profit After Tax*: Rs 1,145 Mn
EBITDA from operations margin 27% Profit after Tax* margin 13% PAT* 4% YoY
9 Months FY24 Financial Highlights
Revenue from Operations: 17% YoY
Total Revenue: Rs 26,462 Mn Reported EBITDA: Rs 7,720 Mn Profit After Tax*: Rs 3,299 Mn
Updated guidance: Revenue growth for the full year around double digits on a constant currency basis compared to earlier guidance of mid teens growth
EBITDA from operations margin 27% PAT* 16% YoY
*before exceptional items
Putting Science to Work
5
2
Syngene – Putting Science to Work
Partner in innovation: #Putting science to work
Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients
We offer integrated solutions across research, development and manufacturing
Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals
Our team includes more than ~6,000 scientists out of total ~8,500+ headcount, operating across 3 state‐of‐ the‐art campuses located in India’s leading life science hubs: Bangalore, Mangalore and Hyderabad
Established track record in discovery research and development for small and large molecules. Emerging presence in commercial manufacturing
Putting Science to Work
7
Our journey so far
Globalization and strategic collaboration • Expanded into formulations development • Contract with Endo Pharmaceuticals to develop novel anti cancer
biological therapeutic molecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion
Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status by the Government of India
1993 – 2000
2010 – 2014
2001 – 2009
Expansion • Expanded service offerings to
include chemical development, safety assessment, biologics development
• Collaboration with BMS to set
up BBRC, Syngene’s first dedicated R&D Center
2015 – 2018
IPO and further collaborations • IPO and listing • Collaboration with Amgen to set up a dedicated R&D center
2019 – 2024
Continued investments and growth • Expanded collaboration with BMS,
Amgen and Zoetis
• Expansion of IDD platform •
Laboratory capacity expansion in Bangalore and Hyderabad • Expansion in Mangalore for
commercial API manufacturing • Capacity and capability addition in
Biologics manufacturing
• Entered in long‐term partnership
with Zoetis for Biologics commercial‐scale manufacturing • Commissioned sterile fill‐finish
facility in Bangalore
• Acquired multi‐modal biologics
manufacturing facility from Stelis Biopharma Ltd
Putting Science to Work
8
Key facts and figures
400+ active clients
13 out of top 15 pharma companies are clients
400+ patents held with clients
World class infrastructure 3 campuses in Bangalore, Hyderabad and Mangalore qualified to meet international standards
Rs. 45,589 Mn (US$567Mn*) Gross Block of Investments ^
Rs. 32,638 Mn (US$406Mn*) FY23 Revenue
Rs. 4,644 Mn (US$58Mn*) FY23 PAT
~8,500+ headcount including ~6,000+ talented scientists
75% energy from renewable sources
All figures are as on March 31, 2023, unless otherwise specified. @ ca. Rs 80 /US$
^Tangible and Intangible Assets
Putting Science to Work
9
Our strategic priorities
Research: Discovery Services Provide end‐to‐end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities
Development and Manufacturing Services – Small Molecules Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions
Secure US FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects
Research: Dedicated Centers Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows
Development and Manufacturing Services – Large Molecules Drive an integrated approach for biologics development and manufacturing to provide a one‐stop‐ shop capability from drug discovery to commercial manufacturing for biologics
Accelerate capacity build‐up
Operational Excellence Focus on customer delivery through operational excellence
People Develop strong leaders and managers while offering all employees career‐ long learning opportunities
Environmental, Social and Governance (ESG) Committed to Science‐based targets and operate in a responsible and sustainable manner.
Putting Science to Work
10
Our broad capabilities, spanning the value chain, facilitate integration and captures additional benefits for clients Research business
Development and Manufacturing business
Discovery Services
Dedicated R&D Centers
Development Services
Manufacturing Services
Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
SynVent ‐ our proprietary platform for Integrated Drug Discovery
SARchitect‐ our proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies
Ring‐fenced infrastructure for exclusive operations for an individual client
Pre‐clinical to clinical trials
Manufacturing of small and large molecules for commercial supplies
Dedicated, multi‐disciplinary team of scientists
Access to entire Syngene ecosystem for specialist research and development operations
Drug substance and drug product development
cGMP‐compliant facilities
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
State‐of‐the art API manufacturing and Biologics manufacturing facilities
cGMP‐compliant manufacturing of clinical supplies, and registration batches for small molecules
Putting Science to Work
11
Sustained investment in skilled workforce and world class infrastructure: a catalyst for expanded client base and strong revenue growth
Constantly expanding skilled workforce
Growing Growing Infrastruc infrastructure ture
Increasing Increasing Client client base Base
High Strong revenue Revenue growth Growth
Number of scientists 2.4x of *FY16
6000+
2500+
More than doubled infrastructure that is qualified to meet international standards
2
60% + increase in client base
~3x revenue from FY16
400+
32
0.9
250+
11
FY16
FY23
FY16
FY23
FY16
FY23
FY16
FY23
Infrastructure (in Million sq. ft.)
INR Bn
12
* Year of IPO
Putting Science to Work
12
Strategic investments augment cash flows and EPS, driving consistent shareholder returns
Improving EPS
Growing Infrastruc ture
Increasing operating cash flow
Increasing High Cash Client Flow Base
Increasing High market Revenue Soaring Growth Market capitalization Capitaliza tion
EPS doubled since *FY16
Annual operating cashflow 2.6 x of FY16
3x market capitalization since FY16
11.6
8.2
5.7
FY16
FY23
INR
3.1
FY16
FY23
INR Bn
239
FY23
77
FY16
INR Bn
13
* Year of IPO
Putting Science to Work
13
3
Syngene strengths
Syngene strengths
A global scale CRO/CDMO •
Integrated Drug Discovery, Development and Manufacturing service provider
• Small and large molecules, ADCs, oligonucleotides • Listed on Indian Stock Exchanges (NSE and BSE)
Solutions through innovation • IP fully assigned to clients • Track record of data management and
security
• Over 400+ patent filings by clients recognizing Syngene scientists
Quality matters • Fully digitized quality organization • Strong compliance track record with global regulators • US FDA, EMA and PMDA approved, GLP certified, AAALAC
accredited facilities
• 78 client and regulator audits in the last financial year
Science in our DNA •
Located in 3 top India life science hubs: Bangalore, Mangalore and Hyderabad
• ~6000+ qualified scientists including ~500 PhDs (~6,000+
total headcount) Resilient supply chain management
• • 2 Mn+ sq. ft. world‐class R&D and manufacturing
infrastructure
Blue chip client list + 400+ active clients • Partnering with large / mid‐size / emerging
biopharma and other industries
• Clients concentrated in US, Europe & Japan • Track record of working with diverse industry
sectors
Making a difference • Partnerships have delivered numerous clinical candidates • Delivery history for integrated CMC programs up to clinical trials and beyond
Putting Science to Work
15
Our end‐to‐end platform enables us to be a 'one‐stop‐shop' for discovery, development and manufacturing (small molecules and biologics)
Discovery
Development
Manufacturing
Chemistry
Drug Substance
Small Molecules
Biologics
Biology
Drug Product
Clinical Supplies
Integrated Drug Substance – Drug Product
HPAPI
Safety Assessment
Specialty Molecules
Antibody-Drug Conjugates
Oligonucleotides
Integrated Drug Discovery
Therapeutic Antibody Discovery & Engineering; Cell Line Development
HPU* (Phase 1)
Bio Analytical Lab (Large Molecules)
Stability & Analytical Services
Commercial Supplies
Bioprocess Development, Process Characterisation, Clinical Manufacturing (Microbial & Mammalian)
Computational and Data Sciences: Bioinformatics, integrative analysis, target dossiers, systems modeling, cheminformatics and AI
16
* Human Pharmacology Unit
Putting Science to Work
16
Experienced workforce: building capabilities and careers
~8,500+ total headcount
6000+ scientists delivering high quality solutions – create a competitive edge
PhDs Master's Degree
Others
20%
9%
71%
All figures are as on March 31, 2023
Inspiring technical excellence and providing opportunities to grow
Nurturing young talent and enhancing science skills
• Syngene Training Academy offers new graduate recruits a six‐month extended induction to help them understand the Company’s vision and values while acquiring the skills to be an industrial scientist
• Science Certification Program is open to all employees to enhance their capabilities keep their
skills up to date and provide opportunities for continuous learning
Developing leaders and managers
• Emerging Leaders Development Program is designed to help strong managers transition from
managerial to leadership roles
• Manager Development Program is designed for first‐ and second‐line managers to develop
basic management skills and performance management to help them manage their teams and ensure that they are making a positive contribution to the organizational goals
Promoting workplace diversity
discrimination and provide a workplace where all employees can deliver their best work • Support provided to parents of young families. 28% of our workforce are female and 20% of
• The Company has strong equal opportunity policies to protect against all forms of
senior management positions are held by females
Putting Science to Work
17
Extended our state‐of‐the‐art infrastructure & new capabilities in different locations within India to meet our strategic partners needs…
HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene’s capabilities are housed today
Fully functional R&D Centre at Genome Valley, Hyderabad, India
Biologics Discovery development & and 2x manufacturing plants in Bangalore, India
API manufacturing Commercial manufacturing to support product launch located at Mangalore, India
18
Putting Science to Work
18
We currently operate a range of successful collaboration models
Dedicated R&D Labs
• Dedicated scientific and support
personnel customized and managed to partner requirements
• Dedicated infrastructure implemented and maintained by Syngene based upon partner specifications • Access to additional R&D,
Manufacturing and support functions at Syngene
• Long‐term (5‐7 years) contractual
commitment
Full time equivalent (FTE) • Dedicated scientific resources
selected from partner‐specified disciplines
• Deliverables and team composition
evolve as project advances • Typically ~3 year contract term
ensures team continuity, adjustable with specified notice period
• Effective for longer‐term research
commitments
Fee For service (FFS)
Risk‐reward
• Flexible, on‐demand resources with
• Rewards based on clearly defined,
targeted skill sets
• Clearly defined project, limited in
scope and deliverables
• Effective way to managed fluctuating
demand, ad‐hoc requests or uncertain quantity of work
pre‐agreed milestones • Project scope spans drug
discovery, product development or truly end to end across both
… and are open to any single or combination of above
19
Putting Science to Work
19
Our experience spans multiple industry segments and partners us with global leaders across the world…
Large & Mid‐Sized BioPharma
Emerging BioPharma (EBP)
Animal Health
AgroChem
CPG
Chemicals/ Polymers
Putting Science to Work
20
Operational robustness driving strategy execution
Continuous improvement embedded in operations driven by certified operational leaders Six Sigma Black Belt certified staff in each service line and support function Green belt certified staff across operations All employees white belt certified
Quality management system: digitized and audit‐ready 80 customer and regulator audits in the last financial year 8 successful USFDA audits in the last 4 years
Client‐focused commercial organization Leaders based in the US, Europe, UK and Asia Close to client locations
Focused execution through strong Project Management Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects
Digital as a differentiator AI capability in all research teams IoT for maintenance and infrastructure reliability Data Management, IT infrastructure and security systems to strengthen our proposition as a strategic partner to clients
Strategic Sourcing that makes a difference Strategic supplier management to avoid supply chain disruption Supply distributed across the world to ensure business continuity
Putting Science to Work
21
We are harnessing digitization and automation through our Lab 4.0 strategy
At Syngene, we have adopted Lab 4.0, deploying technology for compliance, as an optimizer and as an augmenter
Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements
Online management of specifications, procedures, policies, checklist, manuals, BMR, SMF, TTD, protocol, reports
Manage QC workflow, integrates instrument and manage samples and associated information
Laboratory Information Management Systems (LabWare LIMS)
Document Management Systems (DMS)
TrackWise
• Online document storage and
issuance
• Online tracking of files
Radio Frequency Identification System(RFID)
Learning Management Systems (LMS)
Digitize all paperwork related to Quality Management system with no manual Intervention and automated notifications
22
Online Training Platform which tracks learner progress and performance
Putting Science to Work
22
Committed to safety and sustainability
Safety is our first priority •
Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures Risk assessments are an integral part of our operation: a proactive approach in incident prevention Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees Lost time injury frequency rate (LTIFR ): 0.08 69,280 hours of EHSS training
•
•
•
•
Committed to environmental protection •
Committed to Science‐based targets for greenhouse gases 90+% of total hazardous and non‐hazardous waste recycled 75% of energy procured from green energy sources 3.8% YoY reduction in energy usage 2683 MT equivalent CO2 savings from energy conservation 52834 MT equivalent CO2 savings from green power. 40% YoY freshwater savings achieved 71389 KL fresh water saved from recycling, reusing and rainwater harvesting. 1021 KL water rainwater harvested
•
•
•
•
•
•
•
•
Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development Refer to the ESG Report on our website to know more
All figures are as on March 31, 2023, unless otherwise specified
Putting Science to Work
23
International accreditations
• USFDA,OHSAS 18001
• GLP, cGMP, AAALAC & CPCSEA Certified facilities
•
•
•
CAP accreditation, ISO/IEC 27001:2013 accreditation
EMA and PMDA approved, AAALAC accredited facility
The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL)
Putting Science to Work
24
We have consistently received industry recognition for our scientific capability and business excellence
•
•
CMO Leadership Award Winner 2020 ‐ under Categories: Capabilities, Compatibility, Expertise and Service Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia— Viral Clearance and Safety Testing’
• Great Place to Work Certified™ Company •
(ASSOCHAM) CSR & NGO Awards 2020 for our contribution to COVID‐19 relief work in Karnataka.
• •
CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma CMO Leadership Award Champion 2022 ‐ Presented by Life Science Leader and Outsourced Pharma
• Golden Peacock Award for Excellence in Corporate Governance for 2021 by the Institute of
•
•
Directors at the 'Golden Peacock Awards Ceremony’ The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for ‘Best Unique or Innovative Leadership Program’ The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for ‘Best Advance in Compliance Training’
• Asia Pacific Biologics CMO Excellence Awards 2022 ‐ For Quality • • Most Preferred Workplace 2022 ‐ Award by MarksmenDaily.com
Biopharma Honours Award 2022 ‐ For Viral Testing Facility by Informa Markets
• Golden Peacock National Quality
Award 2023 For meeting the overall requirements of the Golden Peacock Excellence Model Biopharma Excellence Awards 2023 For Best Contract Development and Manufacturing Organization (CDMO)
•
2019
2020
2021
2022
2023
9M 2024
•
•
•
•
Ranked as one of the 25 fastest growing companies in India by Outlook Business CMO Leadership Awards 2019 ‐ Presented by Life Science Leader Magazine FICCI CSR Award for Environmental Sustainability ‐ At the 17th Edition of the awards in New Delhi Safe Workplace Champion Award ‐ At the 8th Manufacturing Supply Chain Summit and Awards Best Leadership Development Program for Middle Management Award ‐ At the 6th Global Training and Development Leadership Awards India Pharma Award 2019 ‐ For “Excellence in Contract Research and Manufacturing Services” at CPhI & P‐MEC India Expo. • Utthama Suraksha Puraskar 2019 ‐ (Pharma and Chemical
•
•
Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards
• Dream Companies to Work Award at the 29th Edition of the World HRD Congress
• Golden Peacock Award 2023: For risk
Awards.
• Asian Leadership Award for Excellence in Branding and Marketing in the Contract
•
•
•
•
Research Development and Manufacturing category CRISIL awards Syngene Top score among Indian Pharma ‐ for Environment Safety Governance (ESG) Syngene ranked #69 in Fortune India magazine's list of 'Top 100 Indian wealth creators 2021’ India Pharma Awards 2021 for Operational Excellence–Manufacturing organized by Informa Markets, India Best Governed Company in the Listed Segment: Medium Category at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
• Most Innovative New Learning Programme at the L&D Vision & Innovation Award
organized by Transformance Forums
• Mahatma Award 2021 under Health & Wellbeing Category •
Best Corporate Foundation Award at the World CSR Congress
management practices under the Pharmaceutical sector category.
•
• Awarded India Best Managed Company by Deloitte • Kaizen Excellence Awards:, Won four gold awards at QCFI under different categories Supply Chain Champion Award, 2023 : Winner in the ISCM Supply Chain Ranking in the pharmaceutical sector Best Overall Sustainable Performance (Pharmaceutical) 2023 at the 2nd Edition India Sustainability Conclave & Awards 2023 Excelled at CII National Six Sigma Competition winning 4 Platinum awards.
•
•
Putting Science to Work
25
Robust risk management framework
Syngene has a risk management framework to identify, monitor, report and manage risk Every risk owner monitors and manages risks relevant to their area of responsibility
Executive Committee (EC)
Board of Directors(BOD)
•
Identify and mitigate risk in respective business areas
•
Sign‐off on Enterprise Risk Framework annually
• Review and approve the key
updates to enterprise risks and deep‐dive into few risk areas every quarter
•
Sign‐off on Enterprise Risk Framework annually
• Ensure that appropriate measures are in place to mitigate the risks • Review updates to enterprise risks and deep dive into few risk areas every quarter
• Provide strategic direction on
mitigation of risks
• Ensure principal risks are properly
managed
Risk Owner
Board Risk Committee
Risk identification
Risk assessment
Risk analysis and rating
Risk mitigation
Monitoring and reporting
Refer Annual report for complete risk profile and risk mitigation strategy
Putting Science to Work
26
4
Financials
Q3FY24 financial highlights
Particulars
Q3 FY24 Q3 FY23
YoY change
Q2 FY24 QoQ change
Revenue from operations
Other income
Reported revenue
Material costs
Staff costs
Other direct costs
Other expenses
8,535
293
8,828
2,374
2,405
254
1,063
Foreign exchange (gain)/loss, net
124
EBITDA
EBITDA Margin
Depreciation and Finance Cost
PBT
Tax
PAT before exceptional items
PAT Margin
PAT after exceptional items*
2,608
30%
1,189
1,419
274
1,145
13%
1,115
7,859
172
8,031
2,061
2,192
264
876
156
2,482
31%
1,083
1,399
302
1,097
14%
1,097
9%
70%
10%
15%
10%
‐4%
21%
9,101
216
9,317
2,672
2,412
275
1,022
‐21%
179
5%
2,757
10%
1%
‐9%
4%
30%
1,176
1,581
361
1,220
13%
‐6%
35%
‐5%
‐11%
0%
‐8%
4%
‐31%
‐5%
1%
‐10%
‐24%
‐6%
2%
1,167
‐4%
Balance Sheet Highlights
As on 31st December 2023
Shareholders’ funds
Net Fixed assets
Other net assets (1)
Net cash/(debt) (2)
Total Use of Funds
40,284
37,152
‐842
3,974
40,284
*(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL) (1 )Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less ( Trade payables + Others current liabilities) at the end of the year (2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short‐term borrowings + Long‐term borrowings) at the end of the year
All figures in Rs. Mn unless otherwise specified
Putting Science to Work
28
9MFY24 financial highlights
Particulars
Revenue from operations
Other income
Reported revenue
Material costs
Staff costs
Other direct costs
Other expenses
Foreign exchange (gain)/loss, net
EBITDA
EBITDA Margin
Depreciation and Finance Cost
PBT
Tax
PAT before exceptional items
PAT Margin
PAT after exceptional items*
All figures in Rs. Mn unless otherwise specified
9M FY24
9M FY23
YoY change
25,717
21,985
745
481
26,462
22,466
7,274
7,105
805
3,100
458
7,720
29%
3,491
4,229
930
3,299
12%
3,214
5,664
6,347
835
2,561
376
6,682
30%
3,055
3,627
771
2,856
13%
2,856
17%
55%
18%
28%
12%
‐4%
21%
22%
16%
14%
17%
21%
16%
13%
*(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)
Putting Science to Work
29
5
Shareholding and Share Information
Syngene and Biocon Group
Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India’s first Contract Research Organization. Company has 25+ years of experience in novel molecule discovery, development and manufacturing services
Biocon Limited, founded in 1978, is an innovation‐led global biopharmaceuticals company and has majority holding in key operating entities including Syngene
Integrated services: • Discovery research • Development • Manufacturing
small/large molecules
• • •
•
Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs
*
*including operating subsidiaries other than Syngene
Putting Science to Work
31
Shareholding and Share Information
Syngene’s Shareholding Pattern*
0.8%
44.5%
54.8%
Promoter & Promoter Group
Public
ESOP Trust
Syngene’s Share Information*
NSE Ticker
BSE Ticker
Market Cap (Rs. Mn)
% free‐float
Free‐float market cap (Rs. Mn)
Share Outstanding (Mn)
SYNGENE
539268
2,81,993
45%
1,26,897
402
*As on 31 Dec 2023
Putting Science to Work
32
For more details
Visit our website www.syngeneintl.com
https://twitter.com/SyngeneIntl
https://www.linkedin.com/company/syngene‐international‐limited
https://www.facebook.com/syngeneintl/
https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ
IR Contact: Krishnan G/ Suruchi Daga + 91 9819992927/+91 8800176009 investor@syngeneintl.com krishnan.g@syngeneintl.com suruchi.daga@syngeneintl.com
Media Contact: Shotorupa Ghosh +91 8450977080 shotorupa.ghosh@syngeneintl.com
Putting Science to Work
33
Thank you
© 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document.
www.syngeneintl.com
Stay Connected